|
2025
|
G/S
|
Pharmaceutical preparations |
|
|
G/S
|
Providing medical and scientific research information in the field of pharmaceutical research for... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of neurological disorders and nervous system disorders |
|
|
G/S
|
Providing medical and scientific research information in the field of pharmaceutical research Pro... |
|
|
Invention
|
Methods of treatment of neurological disorders. The present disclosure is generally directed to m... |
|
|
Invention
|
Methods of treating parkinson's disease with t-type calcium channel modulators. Described herein,... |
|
|
G/S
|
Providing medical and scientific research information in the
field of pharmaceuticals for neurol... |
|
2024
|
Invention
|
Compounds and their methods of use.
The present invention is directed to, in part, fused heteroa... |
|
|
Invention
|
Ion channel modulators.
The present invention is directed to, in part, fused heteroaryl compound... |
|
|
G/S
|
Research and development in the fields of neurological disorders and central nervous systems diso... |
|
|
Invention
|
Methods of treatment of scn2a-related disorders.
Provided are methods of treating a subject with... |
|
|
Invention
|
Determining effect of a drug based on brain activity and a trained machine learning model. A comp... |
|
|
Invention
|
Elsunersen / prax-222 for use in the treatment of scn2a-related disorders. Provided are methods o... |
|
|
G/S
|
Providing medical and scientific research information in the field of pharmaceuticals for neurolo... |
|
|
Invention
|
Formulations of t-type calcium channel modulators and methods of use thereof.
Described herein, ... |
|
|
Invention
|
Ion channel modulators.
Provided, in part, are compounds of Formula I:
Provided, in part, are ... |
|
|
Invention
|
Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5... |
|
|
Invention
|
High strength single unit dose formulations and methods of use thereof. e.g.,e.g.,e.g., e.g., ess... |
|
|
Invention
|
Methods of treating essential tremor. The present disclosure relates to methods of treating essen... |
|
2023
|
Invention
|
Kcnt1 inhibitors comprising a sulfonamide ring core and methods of use. Disclosed herein are comp... |
|
|
Invention
|
Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use. Disclosed ... |
|
|
Invention
|
A positive allosteric modulator. The invention relates to salts of Compound 1, crystalline forms ... |
|
|
Invention
|
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α... |
|
|
Invention
|
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators. The present invention is d... |
|
|
G/S
|
Research and development in the fields of neurological
disorders and central nervous systems dis... |
|
|
Invention
|
Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use. Disclosed herein ... |
|
|
Invention
|
Methods of use of t-type calcium channel modulators.
Described herein, in part, are methods usef... |
|
|
Invention
|
Methods of use of t-type calcium channel modulators. Described herein, in part, are methods usefu... |
|
|
Invention
|
Treatment of neurological disorders.
The present disclosure is generally directed to methods of ... |
|
|
Invention
|
Kcnt1 inhibitors comprising a pyrazole core and methods of use. Disclosed herein are compounds co... |
|
|
Invention
|
Kcnt1 inhibitors comprising a thiophene core and methods of use. Disclosed herein are compounds c... |
|
|
Invention
|
Treatment of neurological disorders. de novoSCN1A, SCN2ASCN8ASCN8A, using a compound of Formula (... |
|
|
Invention
|
Kcnt1 inhibitors comprising a thiazole core and methods of use. Disclosed herein are compounds co... |
|
|
Invention
|
Methods for the treatment of neurological disorders. The disclosure relates to methods of treatin... |
|
|
Invention
|
Treatment of neurological disorders. The present disclosure is generally directed to methods of t... |
|
|
Invention
|
T-type calcium channel modulators comprising a piperazine or 1,4-diazepane core and methods of us... |
|
|
Invention
|
T-type calcium channel modulators comprising an azaspirononane core and methods of use thereof.
... |
|
|
Invention
|
T-type calcium channel modulators comprising a diazaspiroheptane core and methods of use thereof.... |
|
|
Invention
|
T-type calcium channel modulators comprising an azaspirononane core and methods of use thereof. D... |
|
|
Invention
|
T-type calcium channel modulators and methods of use thereof. Disclosed herein are compounds for ... |
|
|
Invention
|
Methods of using oligomeric compounds to treat scn2a-related disorders.
The human gene SCN2A enc... |
|
|
Invention
|
Methods of using oligomeric compounds to treat scn2a-related disorders. The human gene SCN2A enco... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of neurological disorders and central nervous syste... |
|
|
Invention
|
Methods of treatment using t-type calcium channel modulators.
Described herein, in part, are met... |
|
|
Invention
|
Methods for the treatment of scn2a-related disorders.
The present disclosure features useful met... |
|
2022
|
Invention
|
Compositions and methods for the treatment of pcdh19 related disorders.
Provided herein are anti... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of
neurological disorders and central nervous syst... |
|
|
Invention
|
Methods of treatment with neuroactive steroids.
The disclosure relates to methods of treating de... |
|
|
Invention
|
Kcnt1 inhibitors and methods of use.
Disclosed herein are compounds comprising an oxadiazole cor... |
|
|
Invention
|
Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof.
Disclos... |
|
2021
|
Invention
|
Kcnt1 inhibitors and methods of use.
The present invention is directed to, in part, compounds an... |
|
|
Invention
|
T-type calcium channel modulators and methods of use thereof.
The present invention is directed ... |
|
2020
|
Invention
|
Formulations of ion channel modulators and methods of preparation and use of ion channel modulato... |
